DU
ATNM icon

Delphia (USA)’s Actinium Pharmaceuticals ATNM Stock Holding History

Delphia (USA)’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,226
Closed -$105K – 283
2022
Q3 		$105K Sell
14,226
-3,443
-19% -$21.4K 0.12% 242
2022
Q2 		$85K Buy
+17,669
New +$100K 0.06% 353

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Delphia (USA)'s ATNM Position: Q4 2022 in Review

Delphia (USA) sold out of Actinium Pharmaceuticals (ATNM) in Q4 2022, closing a stake of 14,226 shares — an estimated $105K sold.

Delphia (USA) first reported a position in ATNM in Q2 2022 and held it in 2 quarters. The position peaked at $105K in Q3 2022. 59 funds tracked by Wall St. Rank hold ATNM as of Q4 2022.

  • Delphia (USA) reported no remaining Actinium Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Delphia (USA) sold 14,226 Actinium Pharmaceuticals shares in Q4 2022, an estimated $105K.
  • Delphia (USA) first reported a position in Actinium Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Delphia (USA)'s Actinium Pharmaceuticals position peaked at $105K in Q3 2022.
  • 59 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2022.

Based on Delphia (USA)'s 13F filing for Q4 2022, filed 14 Feb 2023.